Study S001913

A Phase 3b, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Orforglipron in Adult Participants With Type 2 Diabetes Who Observe Ramadan Fasting (ACHIEVE-RAM)

ClinicalTrials.gov record

Registration

Registration: NCT07613307
Acronym: ACHIEVE-RAM
Study type: INTERVENTIONAL
Phase: PHASE3
Masking: NONE
Status: RECRUITING
Enrollment: 130
Start: 2026-07-15
Primary completion: 2027-05
Lead sponsor: Eli Lilly and Company
Conditions: Diabetes Mellitus, Type 2; Diabetes Melletus; Glucose Metabolism Disorders; Metabolic Disorders; Nutritional and Metabolic Diseases; Endocrine System Diseases; Feeding Behavior; Behavior; Fasting; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptide Receptors; Receptors, G-Protein-Coupled; Receptors, Cell Surface; Membrane Proteins; Proteins; Receptors, Peptide
Interventions: DRUG:Orforglipron
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:J2A-MC-GZPV

Registered primary outcomes

Change from Baseline in Hemoglobin A1C (HbA1c) [Baseline, up to 8 Weeks after Start of Ramadan]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.